Therapeutic patents for the treatment of premenstrual syndrome and premenstrual dysphoric disorder: Historical perpectives and future directions

Expert Opinion on Therapeutic Patents

Volumn 13, Issue 10, 2003, Pages 1491-1499

  Ross, Lori E ^a   Steiner, Meir ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Calcium; Gonadotropin releasing hormone (GnRH); Oral contraceptive; Premenstrual dysphoric disorder (PMDD); Premenstrual syndrome (PMS); Selective serotonin re uptake inhibitor (SSRI)

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 4 AMINOBUTYRIC ACID RECEPTOR; ANDROGEN; CLOMIPRAMINE; DEXFENFLURAMINE; DROLOXIFENE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ETHINYLESTRADIOL PLUS NORETHISTERONE; FLUOXETINE; GABAPENTIN; GANAXOLONE; GONADORELIN DERIVATIVE; LEUPRORELIN; LOW DOSE ORAL CONTRACEPTIVE; MAPROTILINE; MESTRANOL PLUS NORETHISTERONE; MINERAL; NEUROSTEROID; PAROXETINE; PREGABALIN; PREGNANEDIOL; PROGESTERONE; PYRIDOXINE DERIVATIVE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIET SUPPLEMENTATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG RECEPTOR BINDING; FEMALE; FUTUROLOGY; GABAERGIC SYSTEM; HORMONAL THERAPY; HUMAN; LOW DRUG DOSE; NONHUMAN; OSTEOPOROSIS; PATENT; PREMENSTRUAL DYSPHORIC DISORDER; PREMENSTRUAL SYNDROME; REVIEW; SYMPTOMATOLOGY;

EID: 0242467815     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.13.10.1491     Document Type: Review

References (83)

1. MASON-HOHL E: The Diseases of Women by Trotula of Salerno, a Translation of Passionibus Mulierum Curandorum. The Ward Ritchie Press (1940).
2. FRANK RT: The hormonal causes of premenstrual tension. Arch. Neurol. Psychiatry (1931) 26:1053-1057.
3. DALTON K: The Premenstrual Syndrome. William Heineman Medical Books, London, UK (1964).
4. DELANEY J, LUPTON MJ, TOTH E: The Curse: a Cultural History of Menstruation. EP Dutton & Co., Inc., New York, USA (1976).
5. AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and Statistical Manual of Mental Disorders (3rd edn). American Psychiatric Press, Washington, DC, USA (1987):367-369.
6. AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and Statistical Manual of Mental Disorders (4th edn). American Psychiatric Press, Washington, DC, USA (1994):771-774.
7. WORLD HEALTH ORGANIZATION: International Classification of Diseases (10th edn). World Health Organization, Geneva, Switzerland (1996).
8. WOODS NF, MOST A, DERY GK: Prevalence of perimenstrual symptoms. Am. J. Public Health (1982) 72(11):1257-1264.
9. RIVERA-TOVAR AD, FRANK E: Late lineal phase dysphoric disorder in young women. Am. J. Psychiatry (1990) 147(12):1634-1636.
10. ANGST J, SELLARO R, MERIKANGAS KR, ENDICOTT J: The epidemiology of perimenstrual psychological symptoms. Acta Psychiatr. Scand. (2001) 104(2):110-116.
11. COHEN LS, SOARES CN, OTTO MW, SWEENEY BH, LIBERMAN RF, HARLOW BL: Prevalence and predictors of premenstrual dysphoric disorder (PMDD) in older premenopausal women. The Harvard Study of Moods and Cycles. J. Affect. Disord. (2002) 70(2):125-132.
12. WITTCHEN HU, BECKER E, LIEB R, KRAUSE P: Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol. Med. (2002) 32(1):119-132.
13. ROSS LE, STEINER M: A boipsychosocial approach to premenstrual dysphoric disorder. Psychiatr. Clin. N. Am. (2003) 26:529-546.
14. ROCA CA, SCHMIDT PJ, BLOCH M, RUBINOW DR: Implications of endocrine studies of premenstrual syndrome. Psychiatr. Ann. (1996) 26:576-580.
15. RUBINOW DR, SCHMIDT PJ: The treatment of premenstrual syndrome - forward into the past. N. Engl. J. Med. (1995) 332(23):1574-1575.
16. SCHMIDT PJ, NIEMAN LK, DANACEAU MA, ADAMS LF, RUBINOW DR: Differential behavioural effects of gonadal steroids in women with and in those without premenstrual syndrome. N. Engl. J. Med. (1998) 338(4):209-216.
17. ERIKSSON E, SUNDBLAD C, LANDEN M, STEINER M: Behavioural effects of androgens in women. In: Mood Disorders in Women. Steiner M, Yonkers KA, Eriksson E (Eds), Martin Dunitz Ltd, London, UK (2000):233-246.
18. SUNDSTROM POROMAA I, SMITH S, GULINELLO M: GABA receptors, progesterone and premenstrual dysphoric disorder. Arch. Women Ment. Health (2003) 6(1):23-41.
19. ISRAEL SL: Premenstrual tension. JAMA (1938) 110(21):1721-1723.
20. BACKSTROM T, ANDREEN L, BIRZNIECE V et al.: The role of hormones and hormonal treatments in premenstrual syndrome. CNS Drugs (2003) 17(5):325-342.
21. JANOWSKY DS, GORNEY R, KELLEY B: "The curse" - vicissitudes and variations of the female fertility cycle. Part I. Psychiatric aspects. Psychosomatics (1966) 7(4):242-247.
22. GRAHAM CA, SHERWIN BB: The relationship between mood and sexuality in women using an oral contraceptive as a treatment for premenstrual symptoms. Psychoneuroendocrinology (1993) 18(4):273-281.
23. GRAHAM CA, SHERWIN BB: A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive. J. Psychosom. Res. (1992) 36(3):257-266.
24. KAHN LS, HALBREICH U: Oral contraceptives and mood. Expert Opin. Pharmacother. (2001) 2(9):1367-1382.
25. FREEMAN EW, KROLL R, RAPKIN A et al.: Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J. Womens Health Gend. Based Med. (2001) 10(6):561-569.
26. BROWN C, LING F, WAN J: A new monophasic oral contraceptive containing drospirenone. Effect on premenstrual symptoms. J. Reprod. Med. (2002) 47(1):14-22.
27. BORENSTEIN J, YU HT, WADE S, CHIOU CF, RAPKIN A: Effect of an oral contraceptive containing ethinyl estradiol and drospirenone on premenstrual symptomatology and health-related quality of life. J. Reprod. Med. (2003) 48(2):79-85.
28. FREEMAN EW, SONDHEIMER SJ, RICKELS K: Gonadotropin-releasing hormone agonist in the treatment of premenstrual symptoms with and without ongoing dysphoria: a controlled study. Psychopharmacol. Bull. (1997) 33(2):303-309.
29. BROWN CS, LING FW, ANDERSEN RN, FARMER RG, ARHEART KL: Efficacy of depot leuprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial. Obstet. Gynecol. (1994) 84(5):779-786.
30. HAMMARBACK S, BACKSTROM T: Induced anovulation as treatment of premenstrual tension syndrome: a double-blind cross-over study with GnRH-agonist versus placebo. Acta Obstet. Gynecol. Scand. (1988) 67(2):159-166.
31. HUSSAIN SY, MASSIL JH, MATTA WH, SHAW RW, O'BRIEN PM: Buserelin in premenstrual syndrome. Gynecol. Endocrinol. (1992) 6(1):57-64.
32. FENTIMAN IS, CALEFFI M, BRAME K, CHAUDARY MA, HAYWARD JL: Double-blind controlled trial of tamoxifen therapy for mastalgia. Lancet (1986) 1(8476):287-288.
33. GRIFFIN LD, CONRAD SC, MELLON SH: Current perspectives on the role of neurosteroids in PMS and depression. Int. Rev. Neurobiol. (2001) 464:79-492.
34. SMITH S, RINEHART JS, RUDDOCK VE, SCHIFF I: Treatment of premenstrual syndrome with alprazolam: results of a double-blind, placebo-controlled, randomized crossover clinical trial. Obstet. Gynecol. (1987) 70(1):37-43.
35. HARRISON WM, ENDICOTT J, NEE J: Treatment of premenstrual dysphoria with alprazolam: a controlled study. Arch. Gen. Psychiatry (1990) 47(3):270-275.
36. SCHMIDT PJ, GROVER GN, RUBINOW DR: Alprazolam in the treatment of premenstual syndrome: a double-blind, placebo-controlled trial. Arch. Gen. Psychiatry (1993) 50(6):467-473.
37. WANG M, SEIPPEL L, PURDY RH, BACKSTROM T: Relationship between symptom severity and steroid variation in women with premenstrual syndrome: study on serum pregnenolone, pregnenolone sulfate, 5α-pregnane-3,20-dione and 3α-hydroxy-5α-pregnan-20-one. J. Clin. Endocrinol. Metab. (1996) 81(3):1076-1082.
38. RAPKIN AJ, MORGAN M, GOLDMAN L, BRANN DW, SIMONE D, MAHESH VB: Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obstet. Gynecol. (1997) 90(5):709-714.
39. MONTELEONE P, LUISI S, TONETTI A et al.: Allopregnanolone concentrations and premenstrual syndrome. Eur. J. Endocrinol. (2000) 142(3):269-273.
40. FREEMAN EW, FRYE CA, RICKELS K, MARTIN PA, SMITH SS: Allopregnanolone levels and symptom improvement in severe premenstrual syndrome. J. Clin. Psychopharmacol. (2002) 22(5):516-520.
41. GASIOR M, CARTER RB, WITKIN JM: Neuroactive steroids: potential therapeutic use in neurological and psychiatric disorders. Trends Pharmacol. Sci. (1999) 20(3):107-112.
42. NICOLSON A, LEACH JP: Future prospects for the drug treatment of epilepsy. CNS Drugs (2001) 15(12):955-968.
43. FELBERBAUM RE, DIEDRICH K: Gonadotropin-releasing hormone antagonists: will they replace the agonists? Reprod. Biomed. Online (2003) 6(1):43-53.
44. STEINER M, PEARLSTEIN T: Premenstrual dysphoria and the serotonin system: pathophysiology and treatment. J. Clin. Psychiatry (2000) 61(Suppl. 12):17-21.
45. ERIKSSON E, LISJO P, SUNDBLAD C, ANDERSSON K, ANDERSCH B, MODIGH K: Effect of clomipramine on premenstrual syndrome. Acta Psychiatr. Scand. (1990) 81(1):87-88.
46. SUNDBLAD C, MODIGH K, ANDERSCH B, ERIKSSON E: Clomipramine effectively reduces premenstrual irritability and dysphoria: a placebo-controlled trial. Acta Psychiatr. Scand. (1992) 85(1):39-47.
47. ERIKSSON E, HEDBERG MA, ANDERSCH B, SUNDBLAD C: The serotonin re-uptake inhibitor paroxetine is superior to the noradrenaline re-uptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology (1995) 12(2):167-176.
48. STEINER M, STEINBERG S, STEWART D et al.: Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group. N. Engl. J. Med. (1995) 332(23):1529-1534.
49. LIN J, THOMPSON DS: Treating premenstrual dysphoric disorder using serotonin agents. J. Womens Health Gend. Based Med. (2001) 10(8):745-750.
50. COHEN LS, MINER C, BROWN EW et al.: Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries. Obstet. Gynecol. (2002) 100(3):435-444.
51. STEINER M, KORZEKWA M, LAMONT J, WILKINS A: Intermittent fluoxetine dosing in the treatment of women with premenstrual dysphoria. Psychopharmacol. Bull. (1997) 33(4):771-774.
52. HALBREICH U, BERGERON R, YONKERS KA, FREEMAN E, STOUT AL, COHEN L: Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obster. Gynecol. (2002) 100(6):1219-1229.
53. MINER C, BROWN E, MCCRAY S, GONZALES J, WOHLREICH M: Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial. Clin. Ther. (2002) 24(3):417-433.
54. PEARLSTEIN T: Selective serotonin re-uptake inhibitors for premenstrual dysphoric disorder: the emerging gold standard? Drugs (2002) 62(13):1869-1885.
55. WYATT KM, DIMMOCK PW, O'BRIEN PM: Selective serotonin re-uptake inhibitors for premenstrual syndrome. Cochrane Database Syst. Rev. (2002) (4):CD001396.
56. FARVOLDEN P, KENNEDY SH, LAM RW: Recent developments in the psychobiology and pharmacotherapy of depression: optimising existing treatments and novel approaches for the future. Expert Opin. Investig. Drugs (2003) 12(1):65-86.
57. FREEMAN EW, RICKELS K, YONKERS KA, KUNZ NR, MCPHERSON M, UPTON GV: Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstet. Gynecol. (2001) 98(5Pt1):737-744.
58. HSIAO MC, LIU CY: Effective open-label treatment of premenstrual dysphoric disorder with venlafaxine. Psychiatry Clin. Neurosci. (2003) 57(3):317-321.
59. LANDEN M, ERIKSSON O, SUNDBLAD C, ANDERSCH B, NAESSEN T, ERIKSSON E: Compounds with affinity for serotonergic receptors in the treatment of premenstrual dysphoria: a comparison of buspirone, nefazodone and placebo. Psychopharmacology (2001) 155(3):292-298.
60. SCHNEIDER LS, SMALL GW, HAMILTON SH, BYSTRITSKY A, NEMEROFF CB, MEYERS BS: Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial. Am. J. Geriatr. Psychiatry (1997) 5(2):97-106.
61. SCHNEIDER LS, SMALL GW, CLARY CM: Estrogen replacement therapy and antidepressant response to sertraline in older depressed women. Am. J. Geriatr. Psychiatry (2001) 9(4):393-399.
62. SOARES CN, POITRAS JR, PROUTY J, ALEXANDER AB, SHIFREN JL, COHEN LS: Efficacy of citalopram as a monotherapy or as an adjunctive treatment to estrogen therapy for perimenopausal and postmenopausal women with depression and vasomotor symptoms. J. Clin. Psychiatry (2003) 64(4):473-479.
63. AMSTERDAM J, GARCIA-ESPANA F, FAWCETT J et al.: Fluoxetine efficacy in menopausal women with and without oestrogen replacement. J. Affect. Disord. (1999) 55(1):11-17.
64. YONKERS KA, BRADSHAW KD, HALBREICH U: Oestrogens, progestins and mood. In: Mood Disorders in Women. Steiner M, Yonkers KA, Eriksson E (Eds), Martin Dunitz, London, UK (2000):207-232.
65. STOKES J, MENDELS J: Pyridoxine and premenstrual tension. Lancet (1972) 1(7761):1177-1178.
66. 6. Br. J. Nutr. (1999) 81(1):7-20.
67. 6 in the treatment of premenstrual syndrome: systematic review. Br. Med. J. (1999) 318(7195):1375-1381.
68. THYS-JACOBS S: Micronutrients and the premenstrual syndrome: the case for calcium. J. Am. Coll. Nutr. (2000) 19(2):220-227.
69. THYS-JACOBS S, CECCARELLI S, BIERMAN A, WEISMAN H, COHEN MA, ALVIR J: Calcium supplementation in premenstrual syndrome: a randomized crossover trial. J. Gen. Intern. Med. (1989) 4(3):183-189.
70. THYS-JACOBS S, STARKEY P, BERNSTEIN D, TIAN J: Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Am. J. Obstet. Gynecol. (1998) 179(2):444-452.
71. PENLAND JG, JOHNSON PE: Dietary calcium and manganese effects on menstrual cycle symptoms. Am. J. Obstet. Gynecol. (1993) 168(5):1417-1423.
72. BUDEIRI D, LI WAN PO A, DORNAN JC: Is evening primrose oil of value in the treatment of premenstrual syndrome? Control. Clin. Trials (1996) 17(1):60-68.
73. FUGH-BERMAN A, KRONENBERG F: Complementary and alternative medicine (CAM) in reproductive-age women: a review of randomized controlled trials. Reprod. Toxicol. (2003) 17(2):137-152.
74. BENASSAYAG C, PERROT-APPLANAT M, FERRE F: Phytoestrogens as modulators of steroid action in target cells. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. (2002) 777(1-2):233-248.
75. MORTON MS, ARISAKA O, MIYAKE N, MORGAN LD, EVANS BA: Phytoestrogen concentrations in serum from Japanese men and women over 40 years of age. J. Nutr. (2002) 132(10):3168-3171.
76. MERIKANGAS KR, FOELDENYI M, ANGST J: The Zurich Study - XIX. Patterns of menstrual disturbances in the community: results of the Zurich Cohort Study. Eur. Arch. Psychiatry Clin. Neurosci. (1993) 243(1):23-32.
77. DAN AJ, MONAGLE L: Sociocultural influences on women's experiences of perimenstrual symptoms. In: Premenstrual Dysphorias: Myths and Realities. Gold JH, Severino SK (Eds), American Psychiatric Press, Washington, DC, USA (1994):201-212.
78. CHANG AM, HOLROYD E, CHAU JP: Premenstrual syndrome in employed Chinese women in Hong Kong Health Care Women Int. (1995) 16(6):551-561.
79. JOHNSON TM: Premenstrual syndrome as a western culture-specific disorder. Cult. Med. Psychiatry (1987) 11(3):337-356.
80. ANSON O: Exploring the bio-psycho-social approach to premenstrual experiences. Soc. Sci. Med. (1999) 49(1):67-80.
81. KRONENBERG F, FUGH-BERMAN A: Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. Ann. Intern. Med. (2002) 137(10):805-813.
82. NAFTOLIN F, GUADALUPE STANBURY M: Phytoestrogens: are they really estrogen mimics? Fertil. Steril. (2002) 77(1):15-17.
83. MITWALLY MF, KAHN LS, HALBREICH U: Pharmacotherapy of premenstrual syndromes and premenstrual dysphoric disorder: current practices. Expert Opin. Pharmacother. (2002) 3(11):1577-1590.